Neurodegenerative disease research has been trapped in a cycle of failure for decades, with Alzheimer's disease posting a 99.6% failure rate between 2002 and 2012, but a shift toward multi-arm platform trials could fundamentally change how researchers test new treatments. Instead of running separate, single-hypothesis trials that each test one drug against a placebo, researchers are now advocating for a different architecture: testing multiple candidates simultaneously against a shared control group, allowing promising treatments to be expanded and failing ones to be dropped mid-trial without compromising scientific rigor.

What's Wrong With the Current Trial Design for Neurological Diseases?

The traditional approach to testing Alzheimer's and Parkinson's treatments has created a structural problem that goes beyond the inherent difficulty of these diseases. When a standard Phase 2 randomized controlled trial fails, which happens most of the time, the scientific community learns only one narrow fact: that this specific compound, at this specific dose, in this specific patient population, over this specific timeframe, did not work. Everything else remains unknown.

The numbers tell the story. Between 2002 and 2012, roughly 244 compounds entered Alzheimer's disease trials, and only one gained FDA approval, yielding that 99.6% failure rate. Parkinson's disease and motor neuron disease show comparable patterns. The problem is not just that the biology is difficult; it is that the trial infrastructure makes the difficulty worse.

Each failed trial also creates a cascade of operational losses. When a site completes a failed study, the patient data gets locked away in a sponsor's archive, the site goes dark, and the next trial must start from scratch. A new site needs 12 to 18 months of credentialing, institutional review board approval, and patient screening setup before enrolling the first participant. This means years of lost time and resources between attempts.

How Could Multi-Arm Platform Trials Change the Game?

Multi-arm multi-stage (MAMS) platform trials operate on a fundamentally different principle. Instead of running isolated trials, multiple treatment arms test multiple candidates simultaneously against a shared control group. Interim analyses at pre-specified stages allow researchers to drop non-performing arms and expand promising ones without inflating error rates, as long as the design is properly pre-specified.

The shared control group is not just operationally efficient; it is scientifically generative. Because all arms accumulate comparative evidence against the same baseline, researchers learn far more than a sequence of standalone trials could reveal. A site already credentialed and screening-capable for a MAMS platform can add a new treatment arm in weeks, rather than waiting 12 to 18 months.

Two major initiatives are attempting to build this infrastructure. The PRE-MASTODON-AD initiative, funded through the National Institute of Health Research (NIHR), is establishing a platform specifically for Alzheimer's disease and mild cognitive impairment. The Alzheimer's Clinical Trials Consortium (ACTC), funded through the National Institute on Aging (NIA), is creating a standing academic network capable of conducting trials across the full Alzheimer's continuum, from prevention to late-stage disease.

What Regulatory and Organizational Barriers Still Exist?

Despite the scientific case for MAMS trials being clear, the field has resisted this shift for decades. The bottleneck has never been scientific imagination; it has been organizational inertia. Sponsors build standalone trials because their internal processes, budget cycles, chemistry and manufacturing controls (CMC) timelines, and regulatory submissions are structured around standalone trials. A MAMS platform requires upfront coordination costs that no single sponsor wants to absorb alone, shared data governance that legal teams flag as competitive risk, and interim decision frameworks that require regulators and sponsors to agree on rules before data exists.

Regulatory progress has accelerated recently. The International Council for Harmonisation (ICH) E20 Guideline on Adaptive Designs for Clinical Trials was endorsed as a Step 2 draft by the ICH Assembly in June 2025, released for public consultation by the European Medicines Agency (EMA) on June 30, 2025, and made available by the FDA on September 30, 2025. This creates the closest thing to a shared adaptive design rulebook that the industry has ever had.

However, a guideline on adaptive designs is not the same as a guideline specifically on platform trials. MAMS architecture introduces regulatory questions that existing guidance only partially addresses. How should a shared control arm be handled when a platform has been running for three years and the standard of care has shifted? What is the regulatory status of a compound that clears one stage but the platform sponsor adds a new comparator arm before the next stage begins? When two arms in the same MAMS platform are owned by different sponsors, who holds the investigational new drug (IND) application and what are the liability partitions ?

Steps to Building Platform Trial Infrastructure for Neurodegenerative Diseases

• Pre-establish sites and credentials: Sites must be credentialed, institutional review board-approved, and screening-capable before a full trial slate begins, so that new treatment arms can be added in weeks rather than months.
• Harmonize biomarker pipelines: Shared protocols and standardized biomarker assessments across sites allow multiple arms to accumulate comparative evidence efficiently and generate disease characterization data that standalone trials cannot produce.
• Create upfront regulatory alignment: Sponsors, regulators, and academic networks must agree on interim decision frameworks and shared data governance rules before trials launch, reducing legal and competitive barriers to collaboration.

What Does This Mean for Rare Disease Approvals?

While the MAMS platform discussion focuses on common neurodegenerative diseases, the FDA is simultaneously expanding pathways for ultra-rare diseases where traditional randomized controlled trials are simply not feasible because the patient population is too small. In February 2026, the FDA released a draft framework designed to keep evidence standards in place while allowing more individualized therapies to move forward when the underlying biology is clear and the data are strong.

The framework is not a blank check. It requires therapies to directly target a known disease cause, with careful attention to natural history data, treatment effect, and whether results are robust enough to rule out chance. The FDA listed several core criteria for consideration:

• Root cause identification: The disease-causing abnormality must be clearly identified and characterized.
• Target specificity: The therapy must target the root cause or a proximate biological pathway, not just a symptom.
• Natural history data: Well-characterized data on untreated patients must be available for comparison.
• Target engagement: Evidence must confirm successful target drugging or editing at the molecular level.
• Clinical outcomes: Improvement must be shown in clinical outcomes, disease course, or biomarkers that are already known to predict benefit.

Several rare-disease approvals this spring illustrate how this framework is working in practice. On March 25, the FDA approved a drug for neurologic manifestations of Hunter syndrome based on a Phase 1/2 single-arm, open-label trial in 47 pediatric patients, with a large drop in cerebrospinal fluid heparan sulfate at 24 weeks. The sponsor is running a randomized trial that is more than 95% enrolled, suggesting confirmatory evidence is still being pursued.

On March 26, the FDA approved leucovorin for FOLR1-related cerebral folate transport deficiency, describing it as the first treatment for that condition. In that case, observational, or real-world, evidence helped support approval when the drug showed clear clinical benefit compared with the disease's natural history. On May 8, the FDA granted its seventh approval under the Commissioner's National Priority Voucher pilot program, approving Bizengri for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 fusion after prior systemic therapy, based on a single-arm trial of 19 patients with an overall response rate of 36.8%.

Even in these hard-to-study diseases, the FDA is still looking for more than a plausible idea. The agency's framework emphasizes root-cause targeting, strong natural history data, evidence that the therapy reaches or edits the intended target, and outcomes that can be tied to actual patient benefit. Small studies still need to be robust enough to reduce the chance that a result happened by luck.

The broader implication is clear: whether through platform trials for common neurodegenerative diseases or streamlined pathways for ultra-rare conditions, the field is moving away from the one-trial-one-target-one-failure cycle that has defined drug development for decades. The question now is whether the regulatory and organizational infrastructure can keep pace with the scientific case for change.